The best website for weight loss injections isn't the cheapest one

The biggest myth: a lower price means a better deal

Most people land on this search expecting a comparison of prices. That's understandable, but for a prescription medicine, price is the wrong test. A listing that shaves £40 off the going rate for a weight-loss pen can only do that by cutting something: clinical oversight, supply-chain verification, aftercare, or all three. The MHRA's enforcement record makes this concrete. Counterfeit tirzepatide pens (some containing insulin instead of the labelled medicine) have been seized across the UK, including from the first illicit domestic manufacturing site, raided in Northampton in October 2025. The fake pens looked genuine. The savings weren't worth it.

That isn't an argument for paying whatever a website asks. It's an argument for checking what you're actually paying for. A transparent, all-in price covering the consultation, prescription, medicine, and delivery tells you something real. A suspiciously low per-pen figure with no mention of a prescriber tells you something real too. The MHRA advises reporting suspect sellers via the Yellow Card scheme, which covers both adverse reactions and counterfeit products.

On the question of cost, there's more to unpack, but cheapest as a headline goal is the wrong frame for a medicine your prescriber needs to review every time you re-order.

What a legitimate weight-loss injection website actually does

A question our prescribers hear most weeks is some version of: "I found the same pen for less elsewhere, is it safe?" The answer always comes back to the same checklist. First, is the pharmacy verifiable on the GPhC register? That's the General Pharmaceutical Council's public database of every registered UK pharmacy premises, if a site isn't on it, it cannot legally dispense prescription medicines in the UK. Second, does a named, GPhC-registered prescriber personally review the consultation, or does an algorithm make the call? Third, does the site ask for identity verification and current weight before issuing a prescription? These aren't bureaucratic boxes. They're the clinical infrastructure that keeps the medicine appropriate for you specifically.

A legitimate service will also tell you where the medicine comes from. Mounjaro and Wegovy should move through the licensed UK supply chain, sourced from Eli Lilly and Novo Nordisk's authorised UK distributors respectively. If a site is vague about sourcing, that vagueness is the answer. You can read more about how weight loss injections work and what the clinical assessment covers before you commit to any provider.

Injection site matters too, and a good service explains it

"Best website" is partly about what happens after you receive your pen. The most common practical question new patients have isn't about the medicine itself, it's about where to inject. Both Mounjaro and Wegovy are administered subcutaneously into the abdomen, thigh, or upper arm, rotating the site each week to avoid localised reactions. The technique is straightforward, but it's worth getting right. Choosing the right injection site can make a real difference to comfort and absorption, and GLP-1 injection site guidance differs slightly by medicine and individual anatomy.

A good service provides clear guidance on technique and aftercare, and makes a prescriber accessible when questions come up. That means support available seven days a week, not a contact form that takes three days to answer. Side effects with GLP-1 medicines are mostly gastrointestinal (nausea, loose stools, indigestion, fatigue) and are usually most noticeable when starting or after a dose step. Knowing that in advance, and having someone to contact if symptoms feel out of the ordinary, is part of what you're paying for. The NHS patient information for tirzepatide gives a reliable overview of what to expect.

How to choose between Mounjaro and Wegovy

Both are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Mounjaro activates two gut-hormone receptors (GIP and GLP-1); Wegovy activates one (GLP-1 only). In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. The gap narrows with Wegovy's higher 7.2mg dose, approved by the MHRA in early 2026. Which medicine suits you is not a website decision. It's a clinical one, shaped by your health history, any medicines you already take, and how your body responds over the first weeks of treatment. A page exploring which injection might suit you can give more context, and our clinical team reviews every consultation personally before any prescription is issued.